Incidence and risk factors for lymphoma in a single-center inflammatory bowel disease population

Michael V. Chiorean, Bhupesh Pokhrel, Jaya Adabala, Debra Helper, Cynthia S. Johnson, Beth Juliar

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Aims: Previous studies on the risk of lymphoma in inflammatory bowel disease (IBD) have yielded conflicting results. We aim to determine the incidence and risk factors for lymphoma in a large IBD population. Methods: Patients with lymphoma were identified from a single-center IBD database. The standardized incidence ratio (SIR) of lymphoma was estimated using data from the Surveillance, Epidemiology and End Results (SEER) registry. Risk factors for lymphoma were determined by comparing cases with a matched IBD control group. Results: Eleven lymphomas were identified among 3,585 IBD patients during an average of 8.4 years of observation. Three patients were excluded. In the remaining eight, median age at diagnosis was 47 years and mean IBD duration was 20 years (range 7.5-45 years). The SIR for lymphoma was 1.6 [95% confidence interval (CI) 0.6-3.0], and for non-Hodgkin lymphoma (NHL), 1.5 (0.3-2.8). Three lymphoma patients (38%) received prior immunomodulators and two (25%) received biologics, versus 57% and 39% in the control group, respectively (P = 0.4). No correlation was seen with tobacco exposure, disease duration, use, or dose or duration of immunosuppressive therapy. Conclusions: In this IBD cohort, risk of lymphoma was not increased compared with the general population. Risk of lymphoma was not associated with any demographic or therapy-related factors.

Original languageEnglish
Pages (from-to)1489-1495
Number of pages7
JournalDigestive Diseases and Sciences
Volume56
Issue number5
DOIs
StatePublished - May 2011

Fingerprint

Inflammatory Bowel Diseases
Lymphoma
Incidence
Population
Control Groups
Immunologic Factors
Immunosuppressive Agents
Biological Products
Non-Hodgkin's Lymphoma
Tobacco
Registries
Epidemiology
Observation
Demography
Databases
Confidence Intervals
Therapeutics

Keywords

  • Inflammatory bowel disease
  • Lymphoproliferative disease

ASJC Scopus subject areas

  • Gastroenterology
  • Physiology

Cite this

Incidence and risk factors for lymphoma in a single-center inflammatory bowel disease population. / Chiorean, Michael V.; Pokhrel, Bhupesh; Adabala, Jaya; Helper, Debra; Johnson, Cynthia S.; Juliar, Beth.

In: Digestive Diseases and Sciences, Vol. 56, No. 5, 05.2011, p. 1489-1495.

Research output: Contribution to journalArticle

Chiorean, Michael V. ; Pokhrel, Bhupesh ; Adabala, Jaya ; Helper, Debra ; Johnson, Cynthia S. ; Juliar, Beth. / Incidence and risk factors for lymphoma in a single-center inflammatory bowel disease population. In: Digestive Diseases and Sciences. 2011 ; Vol. 56, No. 5. pp. 1489-1495.
@article{c35c09fdff89495c9b151051b9a975b0,
title = "Incidence and risk factors for lymphoma in a single-center inflammatory bowel disease population",
abstract = "Aims: Previous studies on the risk of lymphoma in inflammatory bowel disease (IBD) have yielded conflicting results. We aim to determine the incidence and risk factors for lymphoma in a large IBD population. Methods: Patients with lymphoma were identified from a single-center IBD database. The standardized incidence ratio (SIR) of lymphoma was estimated using data from the Surveillance, Epidemiology and End Results (SEER) registry. Risk factors for lymphoma were determined by comparing cases with a matched IBD control group. Results: Eleven lymphomas were identified among 3,585 IBD patients during an average of 8.4 years of observation. Three patients were excluded. In the remaining eight, median age at diagnosis was 47 years and mean IBD duration was 20 years (range 7.5-45 years). The SIR for lymphoma was 1.6 [95{\%} confidence interval (CI) 0.6-3.0], and for non-Hodgkin lymphoma (NHL), 1.5 (0.3-2.8). Three lymphoma patients (38{\%}) received prior immunomodulators and two (25{\%}) received biologics, versus 57{\%} and 39{\%} in the control group, respectively (P = 0.4). No correlation was seen with tobacco exposure, disease duration, use, or dose or duration of immunosuppressive therapy. Conclusions: In this IBD cohort, risk of lymphoma was not increased compared with the general population. Risk of lymphoma was not associated with any demographic or therapy-related factors.",
keywords = "Inflammatory bowel disease, Lymphoproliferative disease",
author = "Chiorean, {Michael V.} and Bhupesh Pokhrel and Jaya Adabala and Debra Helper and Johnson, {Cynthia S.} and Beth Juliar",
year = "2011",
month = "5",
doi = "10.1007/s10620-010-1430-z",
language = "English",
volume = "56",
pages = "1489--1495",
journal = "Digestive Diseases and Sciences",
issn = "0163-2116",
publisher = "Springer New York",
number = "5",

}

TY - JOUR

T1 - Incidence and risk factors for lymphoma in a single-center inflammatory bowel disease population

AU - Chiorean, Michael V.

AU - Pokhrel, Bhupesh

AU - Adabala, Jaya

AU - Helper, Debra

AU - Johnson, Cynthia S.

AU - Juliar, Beth

PY - 2011/5

Y1 - 2011/5

N2 - Aims: Previous studies on the risk of lymphoma in inflammatory bowel disease (IBD) have yielded conflicting results. We aim to determine the incidence and risk factors for lymphoma in a large IBD population. Methods: Patients with lymphoma were identified from a single-center IBD database. The standardized incidence ratio (SIR) of lymphoma was estimated using data from the Surveillance, Epidemiology and End Results (SEER) registry. Risk factors for lymphoma were determined by comparing cases with a matched IBD control group. Results: Eleven lymphomas were identified among 3,585 IBD patients during an average of 8.4 years of observation. Three patients were excluded. In the remaining eight, median age at diagnosis was 47 years and mean IBD duration was 20 years (range 7.5-45 years). The SIR for lymphoma was 1.6 [95% confidence interval (CI) 0.6-3.0], and for non-Hodgkin lymphoma (NHL), 1.5 (0.3-2.8). Three lymphoma patients (38%) received prior immunomodulators and two (25%) received biologics, versus 57% and 39% in the control group, respectively (P = 0.4). No correlation was seen with tobacco exposure, disease duration, use, or dose or duration of immunosuppressive therapy. Conclusions: In this IBD cohort, risk of lymphoma was not increased compared with the general population. Risk of lymphoma was not associated with any demographic or therapy-related factors.

AB - Aims: Previous studies on the risk of lymphoma in inflammatory bowel disease (IBD) have yielded conflicting results. We aim to determine the incidence and risk factors for lymphoma in a large IBD population. Methods: Patients with lymphoma were identified from a single-center IBD database. The standardized incidence ratio (SIR) of lymphoma was estimated using data from the Surveillance, Epidemiology and End Results (SEER) registry. Risk factors for lymphoma were determined by comparing cases with a matched IBD control group. Results: Eleven lymphomas were identified among 3,585 IBD patients during an average of 8.4 years of observation. Three patients were excluded. In the remaining eight, median age at diagnosis was 47 years and mean IBD duration was 20 years (range 7.5-45 years). The SIR for lymphoma was 1.6 [95% confidence interval (CI) 0.6-3.0], and for non-Hodgkin lymphoma (NHL), 1.5 (0.3-2.8). Three lymphoma patients (38%) received prior immunomodulators and two (25%) received biologics, versus 57% and 39% in the control group, respectively (P = 0.4). No correlation was seen with tobacco exposure, disease duration, use, or dose or duration of immunosuppressive therapy. Conclusions: In this IBD cohort, risk of lymphoma was not increased compared with the general population. Risk of lymphoma was not associated with any demographic or therapy-related factors.

KW - Inflammatory bowel disease

KW - Lymphoproliferative disease

UR - http://www.scopus.com/inward/record.url?scp=79955601728&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955601728&partnerID=8YFLogxK

U2 - 10.1007/s10620-010-1430-z

DO - 10.1007/s10620-010-1430-z

M3 - Article

VL - 56

SP - 1489

EP - 1495

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

SN - 0163-2116

IS - 5

ER -